Looking back at Dror's comments in the last earnings call:
"And actually as you all know, it’s quite difficult to do deals on certain indication and then split it and get someone else to actually sell the drug for another indication. It’s very difficult in the U.S. It’s difficult in most places around the globe. So we are looking for relatively small or very [exclusive] territories where we are going to license the drug for the different indication. Of course, in the deal one can put economy that will actually give us benefits from the different indications, and that’s what we are working on. But the whole idea is that this type of deals shouldn’t harm it any way the global potential deal that we can have.
And again, it can be something that we’ll split geographically between us and strategic partner with the successful results in 2018. But this geographic deal that we’re talking about actually not going to jeopardize any of this big global deals. But it’s going to include all indications. And actually, we are even planning, if it will go forward, to take advantage of one of the territories, which has a significant number of patients with lung cancer. And then of course that could be a good place to do some of the trials as part of global trials."
Dror was pretty much telling us about the deal without telling us about the deal. Sounds like Japan is one of the places that will participate in the "exploratory clinical study of VB-111 in combination with checkpoint inhibitor in lung cancer in Q1 2018."
